Table 1.
Patient demographics and baseline disease characteristics, and distribution of patients by number of prior treatment failures
| Population by number of prior failures |
PBO N = 894 |
GMB 120 mg N = 444 |
GMB 240 mg N = 435 |
Overall N = 1773 |
|
|---|---|---|---|---|---|
| n (%) | 0 | 672 (75.2) | 316 (71.2) | 331 (76.1) | 1319 (74.4) |
| ≥1 | 222 (24.8) | 128 (28.8 | 104 (23.9) | 454 (25.6) | |
| ≥2 | 92 (10.3) | 51 (11.5) | 45 (10.3) | 188 (10.6) | |
| Age, years, mean (SD) | 0 | 41.8 (11.5) | 40.1 (11.7) | 40.1 (11.4) | 41.0 (11.5) |
| ≥1 | 42.0 (10.9) | 42.9 (10.9) | 41.9 (10.6) | 42.3 (10.8) | |
| ≥2 | 43.8 (10.2) | 43.0 (11.6) | 43.8 (9.9) | 43.6 (10.5) | |
| Gender (female), % | 0 | 82.9 | 82.6 | 81.9 | 82.6 |
| ≥1 | 89.2 | 91.4 | 91.4 | 90.3 | |
| ≥2 | 88.0 | 90.2 | 86.7 | 88.3 | |
| Duration of migraine disease, years, mean (SD) | 0 | 20.3 (12.3) | 19.6 (12.2) | 19.0 (11.6) | 19.8 (12.1) |
| ≥1 | 21.3 (13.2) | 22.9 (12.5) | 21.8 (13.1) | 21.8 (13) | |
| ≥2 | 22.9 (13.6) | 22.5 (12.9) | 24.8 (13.7) | 23.2 (13.4) | |
| Migraine headache days per month, mean (SD) | 0 | 9.1 (3.0) | 9.0 (3.0) | 9.0 (2.9) | 9.1 (3.0) |
| ≥1 | 9.2 (2.9) | 9.5 (2.8) | 9.4 (2.9) | 9.3 (2.8) | |
| ≥2 | 9.1 (3.0) | 9.3 (2.8) | 9.9 (2.8) | 9.3 (2.9) | |
| Migraine headache days per month with acute medication use, mean (SD) | 0 | 7.4 (3.5) | 7.2 (3.5) | 7.3 (3.3) | 7.3 (3.5) |
| ≥1 | 7.8 (3.2) | 8.0 (3.5) | 7.9 (3.1) | 7.9 (3.3) | |
| ≥2 | 7.6 (3.4) | 8.2 (3.3) | 8.3 (3.1) | 7.9 (3.3) | |
| MSQ RF‐R, mean (SD)a | 0 | 52.8 (15.6) | 52.8 (15.4) | 49.7 (17.1) | 52.0 (16.0) |
| ≥1 | 50.1 (15.5) | 49.8 (15.4) | 52.1 (14.8) | 50.5 (15.3) | |
| ≥2 | 49.7 (15.2) | 51.9 (14.5) | 55.1 (14.9) | 51.6 (15.0) |
GMB, galcanezumab; MSQ RF‐R, Role Function‐Restrictive domain score of the Migraine‐Specific Quality of Life Questionnaire version 2.1; PBO, placebo.
a
For MSQ RF‐R domain scores: PBO, N = 887; GMB 120 mg, N = 443; GMB 240 mg, N = 430; total population 1760.